Altruist Biologics Receives NMPA Priority Review for Localized Biologic Drug Manufacturing
- Altruist Biologics has secured NMPA priority review for a new drug application for localized biologic drug manufacturing.
- The Hangzhou facility has a total antibody manufacturing capacity of 172,000 liters, with 80,000 liters currently operational.
Operational Impact
The NMPA's acceptance of the NDA will accelerate the transition of manufacturing from overseas to Altruist's domestic facility in China.
Source: PharmaSource RSS
Codis Advances UK Operations with PSD-4 Expansion Following Facility Demolition
- Codis has completed the demolition of redundant facilities at its Haverhill, UK site, paving the way for a new PSD-4 spray dryer construction.
- The PSD-4 expansion will enhance Codis' commercial-scale solvent-based spray drying capacity, enabling clients to manufacture poorly soluble drug candidates.
Operational Impact
The PSD-4 expansion will significantly boost Codis' capacity for producing amorphous solid dispersions, benefiting pharmaceutical clients in the UK.
Source: Contract Pharma Breaking News RSS
Piramal Pharma Solutions Recognized for Innovative Patient-Centric Dashboard at Pithampur Site
- Piramal Pharma Solutions has won the Excellence in Patient Centricity Award for its Integrated Patient Impact Dashboard at the Pithampur site.
- The dashboard tracks an average monthly supply of 39.8 million units across 24 products, reaching a potential 34.08 million lives.
Operational Impact
The dashboard's insights into production and patient reach at the Pithampur site support data-informed decisions that enhance patient safety and quality.
Source: PharmaSource RSS
References
- PharmaSource RSS — Altruist Biologics Receives NMPA Priority Review for Localized Biologic Drug Manufacturing
- Contract Pharma Breaking News RSS — Codis Advances UK Operations with PSD-4 Expansion Following Facility Demolition
- PharmaSource RSS — Piramal Pharma Solutions Recognized for Innovative Patient-Centric Dashboard at Pithampur Site